首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours.
【24h】

Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours.

机译:皮质抑素和MrgX2(一种特定的皮质抑素受体)在人神经内分泌组织和相关肿瘤中的表达。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cortistatin (CST), a novel hormone originally described in the rat, mouse, and human cerebral cortex, displays structural and functional similarities to somatostatin (SRIF). CST binds to all five somatostatin receptors and, differently from SRIF, also binds to MrgX2, which has recently been identified as its specific receptor. Little is known about the distribution of CST and MrgX2 in peripheral non-tumour and neoplastic tissues. The aim of the present study was therefore to determine by immunohistochemistry and mRNA analysis (RT-PCR) the distribution of CST and MrgX2 in 56 human non-tumour and 108 tumour tissues, with special reference to neuroendocrine tissue types. Despite the high level of CST mRNA expression in non-tumour and tumour (both neuroendocrine and non-neuroendocrine) tissues, the presence of immunoreactive CST was confirmed in a subset of gastroenteropancreatic, parathyroid, and pituitary non-tumour cells only, and showed a predominantly focal pattern in most neuroendocrine tumours. Co-localization experiments in the gastroenteropancreatic system demonstrated that the normal CST-producing cells are delta cells, while in the adenohypophysis no preferential co-localization of CST with any of the pituitary hormones was observed. MrgX2 mRNA was variably detected in the hypothalamus, pituitary, thyroid, lung, gastroenteropancreatic tract, testis, and ovary, and was negative in the cerebral cortex, parathyroid, and adrenal, as well as in a variety of tumour types. Conversely, immunolocalization of MrgX2 protein was restricted to neurohypophysis and testis, whilst all tumours analysed were negative. A possible explanation for the discrepancy between RT-PCR and immunohistochemistry is that MrgX2 protein was widely detected in blood vessels, scattered lymphocytes, and gastrointestinal ganglia in both normal and neoplastic samples. The findings demonstrate a selective distribution of CST in normal and neoplastic neuroendocrine tissues, suggesting that CST might have a broader functional role than previously assumed, whereas possible autocrine/paracrine actions via its recently described specific receptor MrgX2 are restricted to selected tissues.
机译:皮质抑素(CST)是最初在大鼠,小鼠和人类大脑皮层中描述的一种新型激素,与生长抑素(SRIF)具有相似的结构和功能。 CST与所有五个生长抑素受体结合,并且与SRIF不同,它还与MrgX2结合,后者最近被确定为其特异性受体。关于CST和MrgX2在周围非肿瘤和肿瘤组织中的分布知之甚少。因此,本研究的目的是通过免疫组织化学和mRNA分析(RT-PCR)确定CST和MrgX2在56个人类非肿瘤组织和108种肿瘤组织中的分布,并特别参考神经内分泌组织类型。尽管在非肿瘤和肿瘤(神经内分泌和非神经内分泌)组织中CST mRNA的表达水平很高,但仅在一部分胃肠胰腺,甲状旁腺和垂体非肿瘤细胞中证实了免疫反应性CST的存在。在大多数神经内分泌肿瘤中主要是局灶性模式。在胃肠胰腺系统中的共定位实验表明,正常的CST产生细胞是δ细胞,而在腺垂体中,未观察到CST与任何垂体激素的优先共定位。在下丘脑,垂体,甲状腺,肺,胃肠道,睾丸和卵巢中可变检测到MrgX2 mRNA,在大脑皮层,甲状旁腺和肾上腺以及多种肿瘤类型中均阴性。相反,MrgX2蛋白的免疫定位仅限于神经垂体和睾丸,而所有分析的肿瘤均为阴性。 RT-PCR与免疫组织化学之间差异的可能解释是,在正常和肿瘤样品中,在血管,分散的淋巴细胞和胃肠道神经节中广泛检测到MrgX2蛋白。这些发现证明了CST在正常和肿瘤性神经内分泌组织中的选择性分布,表明CST可能比以前设想的具有更广泛的功能作用,而通过其最近描述的特异性受体MrgX2可能产生的自分泌/旁分泌作用仅限于选定的组织。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号